Doxorubicin liposomal - Insys Therapeutics

Drug Profile

Doxorubicin liposomal - Insys Therapeutics

Alternative Names: Doxorubicin - liposome encapsulated; LED; Liposomal doxorubicin - Insys Therapeutics; PNU 108112; PNU 112 ONC 0354

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator Georgetown University
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action P-glycoprotein inhibitors; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 11 Jan 2008 Discontinued - Phase-III for Breast cancer in USA (unspecified route)
  • 11 Jan 2008 Discontinued - Phase-III for Prostate cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top